RxDoctor Payments Data

Gilbert Mbeo, MD

Interventional Pain Medicine · Orlando, FLNPI 1396024949

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,885 of the $5,845 with a category attached, or 83.6%. It is spread thinly across 42 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations.

$5,845in general payments, 2019–2025

Across 146 payments — averaging $40.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$860
  • Boston Scientific$780
  • AbbVie$652
  • Nevro Corp.$566
  • Novartis$489
  • Takeda Pharmaceuticals U.S.A., Inc.$443
  • plus $2K from 36 others
$1,370,157in research payments, 2019–2025

Across 16 payments — averaging $85,635 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertex$658K
  • E.r. Squibb & Sons, L.L.C.$401K
  • Eli Lilly$221K
  • Novartis$74K
  • Genentech, Inc.$17K

What the payments were for

  • Speaking & faculty fees$882%
  • Travel & lodging$87215%
  • Food & beverage$4,88584%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,845 in reported general payments places this provider in the 55th percentile of 278 interventional pain medicine providers in Florida.

See all interventional pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$18,088
Medicare patients
74
Services billed
239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Duloxetine Hcl13$1,391
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen27$853
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen26$605
Carbidopa-LevodopaCarbidopa/Levodopa27$520
Oxycodone Hcl13$275
Meloxicam45$200
Pregabalin19$160
Gabapentin15$139
Nortriptyline Hcl15$117

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →